Journal of Experimental Pharmacology and Toxicology
Journal of Experimental Pharmacology and Toxicology (JEPT, ISSN 3091-0595) is an international, peer-reviewed, open access journal, published quarterly in English by the „Victor Babeș” University of Medicine and Pharmacy of Timișoara, Romania.
JEPT publishes high quality original research articles, review and mini-review articles, and clinical case reports on current advances in life sciences, pharmaceutical sciences, preclinical and clinical pharmacology and toxicology, and related disciplines.
Open Access
All articles are freely available online immediately upon publication, without subscription or registration, and are published under the Creative Commons Attribution 4.0 (CC BY 4.0) license. Authors retain the copyright of their work.
Article Processing Charges (APC)
JEPT does not charge any fees to authors: there are no submission, processing or publication charges. All publication costs are supported by the „Victor Babeș” University of Medicine and Pharmacy of Timișoara, Romania.
Peer review
All manuscripts undergo double-blind peer review by at least two independent expert reviewers. The first decision is communicated to the authors approximately 25 days after submission; the average time from submission to online publication is 45 days.
Publication ethics
JEPT follows the ICMJE Recommendations and the COPE Core Practices. Full details are available on the Journal Policies page.
Journal of Experimental Pharmacology and Toxicology (JEPT) is a quarterly, peer-reviewed, open access journal, published in English, that welcomes high quality original research articles, review and mini-review articles, and clinical case reports on current advances in life sciences, pharmaceutical sciences, in preclinical and clinical pharmacology and toxicology, and related disciplines.
The pivotal goal of the journal is to actively contribute to the advancements in life sciences, mainly in pharmaceutical and medical fields by adopting a multidisciplinary approach. Publishing cutting-edge findings and new developments, the journal aims to connect the basic/experimental research with the clinical practice.
The main areas of research of interest for Journal of Experimental Pharmacology and Toxicology (JEPT) are:
A. Pharmaceutical sciences (pharmacology, pharmaceutics, pharmaceutical technology and analysis, medicinal chemistry, pharmacognosy, natural products, drug delivery)
B. Basic and clinical pharmacology (pharmacodynamics and pharmacokinetics, drug mechanisms, pathological mechanisms involved in cancer and other diseases, biomarkers, enzymes, drug metabolism, pharmacogenetics and personalized medicine)
C. Toxicology (mechanistic toxicology, in vitro, in vivo, computational and predictive toxicity methods, toxicity of natural products, nanoparticles and pharmaceuticals, adverse effects of xenobiotics, pharmacovigilance, toxicokinetics, novel techniques for the assessment of toxicity, drug-drug interactions)
D. Drug discovery and development (drug design, development of novel pharmaceutical compounds, target identification and validation, new chemical entities, natural compounds, preclinical and clinical pharmacological and toxicological screening, pathological in vitro and in vivo models, drug delivery, pharmaceutical formulation).
Manuscripts focusing on the following topics are particularly encouraged:
- Cancer research: new models of disease and approaches to drug discovery; translational research
- Chemoprevention and chemotherapeutic studies
- Toxicology studies: in vitro, in vivo, computational and predictive toxicology
- Mechanisms underlying toxicity induced by xenobiotics (pharmaceutical, natural products, chemicals, nanoparticles, etc)
- Clinical case reports describing exposure to toxins
- Pharmacological and toxicological investigations of novel pharmaceutical entities, drug delivery platforms, nanomedicines
- Investigations into drug efficacy and safety within clinical settings, including clinical trials and observational studies to understand pharmacological outcomes in diverse patient populations
- Drug targeting analysis.
We place no restriction on the length of submitted manuscripts and require full disclosure of experimental methods to ensure reproducibility of results. Key features of this journal include:
- Acceptance of manuscripts focused on innovative research proposals and novel research concepts.
- Optional inclusion of supplementary files with comprehensive procedural data, especially if detailed methods cannot be fully covered in the Materials and Methods section.
- Welcoming broader, accessible submissions on research projects funded by public sources to enhance knowledge dissemination.
